Skip to main content

Table 2 Baseline disease characteristics and HRQoL of the biomarker population, by IL-6 tertile

From: High levels of interleukin-6 in patients with rheumatoid arthritis are associated with greater improvements in health-related quality of life for sarilumab compared with adalimumab

 

IL-6 tertile

Low

Medium

High

Adalimumab 40 mg q2w, n (%)

45 (30)

53 (35)

54 (35)

Sarilumab 200 mg q2w, n (%)

55 (37)

47 (32)

46 (31)

CRP (mg/L) mean (± SD) [range]*

5.62 (9.18)

15.24 (17.14)

41.51 (34.14)

[0.2–48.2]

[1.0–120.0]

[2.2–202.0]

ESR (mm/h) mean (± SD) [range]*

38.99 (15.56)

44.96 (20.35)

59.02 (26.48)

[7.0–104.0]

[14.0–130.0]

[4.0–130.0]

Positive RF (> 15 IU/mL), n (%)**

46 (46)

72 (74)

73 (73)

Postive ACPA (≥ 17 U/mL), n (%)**

53 (55)

78 (81)

87 (87)

IL-6, pg/mL, median [range]

2.4 [1.6–7.1]

16.2 [7.2–39.5]

64.7 [39.6–692.3]

Baseline HRQoL scores, mean (± SD) [range]

 SF-36 summary scores (0–100)

  PCS

31.78 (6.16)

30.96 (6.25)

30.36 (6.56)

[16.5–46.0]

[18.4–47.5]

[18.1–52.0]

  MCS*

37.49 (10.47)

38.80 (12.02)

34.98 (12.61)

[12.8–61.6]

[11.4–67.1]

[13.1–66.8]

 SF-36 domain scores (0–100)

  PF

37.02 (20.01)

35.36 (19.10)

31.74 (22.36)

[0.0–85.0]

[0.0–90.0]

[0.0–94.4]

  RP*

37.56 (18.74)

35.75 (19.69)

30.44 (19.58)

[0.0–81.3]

[0.0–100.0]

[0.0–87.5]

  BP*

31.14 (15.25)

27.83 (14.42)

24.63 (16.92)

[0.0–84.0]

[0.0–70.0]

[0.0–74.0]

  GH

33.85 (15.84)

36.75 (14.78)

35.77 (17.54)

[0.0–77.0]

[0.0–82.0]

[0.0–82.0]

  VT

34.50 (16.87)

35.63 (18.04)

31.94 (17.27)

[0.0–75.0]

[0.0–87.5]

[0.0–68.8]

  SF*

48.99 (22.49)

50.63 (25.59)

41.00 (26.77)

[0.0–100.0]

[0.0–100.0]

[0.0–100.0]

  RE*

50.59 (24.26)

51.92 (26.51)

42.67 (28.70)

[0.0–100.0]

[0.0–100.0]

[0.0–100.0]

  MH

50.20 (17.95)

51.80 (20.18)

47.68 (21.00)

[10.0–95.0]

[5.0–100.0]

[5.0–100.0]

  AM-stiffness VAS (0–100 mm)*

64.60 (19.89)

68.01 (19.70)

75.17 (20.33)

[11.0–100.0]

[10.0–100.0]

[16.0–100.0]

  FACIT-fatigue (0–52)

24.12 (9.77)

24.86 (9.80)

21.89 (9.62)

[3.0–50.0]

[1.0–48.0]

[2.0–45.0]

  1. ACPA anti-citrullinated peptide antibody, BP bodily pain, CRP C-reactive protein, ESR erythrocyte sedimentation rate, FACIT Functional Assessment of Chronic Illness Therapy, GH general health, HRQoL health-related quality of life, IL-6 interleukin-6, MH mental health, AM-stiffness duration of morning stiffness visual analog scale, PF physical functioning, q2w every 2 weeks, RE role-emotional, RF rheumatoid factor, RP role-physical, SF social functioning, SF-36 Short Form 36, VAS visual analog scale, VT vitality
  2. *Kruskal-Wallis test nominal p < 0.05
  3. **Chi2 test nominal p < 0.05